Dyne Therapeutics, Inc.’s DYN share price has dipped by 12.10%, which has investors questioning if this is right time to buy.

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

The last time I wrote about Dyne Therapeutics (NASDAQ:DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article ...

BMO forecasts DYNE-101 peak global sales of $4.3 billion by 2035. Dyne plans to start a Registrational Expansion Cohort in H1 2026 for potential accelerated approval. Feel unsure about the market ...

Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at ...

Dyne Therapeutics, Inc. WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Dyne Therapeutics Inc (Symbol: DYN) entered into oversold territory, hitting an RSI reading ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Dyne plans to begin a global Registrational Expansion Cohort with the potential to support a submission for U.S. Accelerated Approval based on biomarker and functional data in H1 2026.